Shanghai Shyndec Pharmaceutical Toekomstige groei
Future criteriumcontroles 1/6
Shanghai Shyndec Pharmaceutical is forecast to grow earnings and revenue by 16% and 7.6% per annum respectively. EPS is expected to grow by 16.1% per annum. Return on equity is forecast to be 10.3% in 3 years.
Belangrijke informatie
16.0%
Groei van de winst
16.1%
Groei van de winst per aandeel
Pharmaceuticals winstgroei | 19.3% |
Inkomstengroei | 7.6% |
Toekomstig rendement op eigen vermogen | 10.3% |
Dekking van analisten | Low |
Laatst bijgewerkt | 15 Oct 2024 |
Recente toekomstige groei-updates
Geen updates
Recent updates
Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2026 | 13,705 | 1,557 | N/A | 2,784 | 2 |
12/31/2025 | 12,876 | 1,377 | N/A | 2,490 | 2 |
12/31/2024 | 12,024 | 1,173 | N/A | 2,202 | 1 |
9/30/2024 | 11,501 | 1,082 | 2,036 | 2,300 | N/A |
6/30/2024 | 11,585 | 1,065 | 2,332 | 2,626 | N/A |
3/31/2024 | 11,776 | 844 | 1,880 | 2,162 | N/A |
12/31/2023 | 12,070 | 692 | 1,363 | 1,720 | N/A |
9/30/2023 | 12,402 | 765 | 2,022 | 2,336 | N/A |
6/30/2023 | 13,017 | 748 | 2,186 | 2,500 | N/A |
3/31/2023 | 13,132 | 729 | 2,402 | 2,708 | N/A |
12/31/2022 | 12,959 | 628 | 2,548 | 2,856 | N/A |
9/30/2022 | 12,954 | 363 | 1,924 | 2,273 | N/A |
6/30/2022 | 12,700 | 367 | 2,115 | 2,503 | N/A |
3/31/2022 | 13,260 | 425 | 1,536 | 1,991 | N/A |
12/31/2021 | 13,945 | 568 | 1,158 | 1,680 | N/A |
9/30/2021 | 13,903 | 649 | 1,148 | 1,712 | N/A |
6/30/2021 | 13,977 | 748 | 966 | 1,524 | N/A |
3/31/2021 | 13,182 | 734 | 1,470 | 2,002 | N/A |
12/31/2020 | 12,556 | 649 | 1,182 | 1,560 | N/A |
9/30/2020 | 12,538 | 713 | 153 | 496 | N/A |
6/30/2020 | 12,156 | 611 | -72 | 371 | N/A |
3/31/2020 | 12,328 | 607 | 293 | 685 | N/A |
12/31/2019 | 12,199 | 656 | 866 | 1,270 | N/A |
9/30/2019 | 11,860 | 703 | 2,418 | 2,839 | N/A |
6/30/2019 | 11,723 | 667 | 2,389 | 2,779 | N/A |
3/31/2019 | 11,386 | 717 | 1,270 | 1,669 | N/A |
12/31/2018 | 11,321 | 706 | 1,270 | 1,669 | N/A |
9/30/2018 | 10,416 | 647 | 2,220 | 2,530 | N/A |
6/30/2018 | 9,791 | 569 | N/A | 2,411 | N/A |
3/31/2018 | 9,260 | 530 | N/A | 2,565 | N/A |
12/31/2017 | 8,518 | 516 | N/A | 2,315 | N/A |
9/30/2017 | 9,086 | 539 | N/A | 1,050 | N/A |
6/30/2017 | 9,124 | 544 | N/A | 869 | N/A |
3/31/2017 | 9,324 | 534 | N/A | 654 | N/A |
12/31/2016 | 9,126 | 477 | N/A | 839 | N/A |
9/30/2016 | 13,514 | 773 | N/A | 1,898 | N/A |
6/30/2016 | 12,126 | 697 | N/A | 1,821 | N/A |
3/31/2016 | 10,388 | 580 | N/A | 1,912 | N/A |
12/31/2015 | 8,988 | 530 | N/A | 1,666 | N/A |
9/30/2015 | 2,829 | 206 | N/A | 254 | N/A |
6/30/2015 | 2,820 | 211 | N/A | 50 | N/A |
3/31/2015 | 2,882 | 203 | N/A | 202 | N/A |
12/31/2014 | 2,749 | 190 | N/A | 259 | N/A |
9/30/2014 | 2,492 | 169 | N/A | 292 | N/A |
6/30/2014 | 2,442 | 159 | N/A | 386 | N/A |
3/31/2014 | 2,317 | 137 | N/A | 129 | N/A |
12/31/2013 | 2,350 | 133 | N/A | 207 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: 600420's forecast earnings growth (16% per year) is above the savings rate (2.9%).
Winst versus markt: 600420's earnings (16% per year) are forecast to grow slower than the CN market (25.8% per year).
Hoge groeiwinsten: 600420's earnings are forecast to grow, but not significantly.
Omzet versus markt: 600420's revenue (7.6% per year) is forecast to grow slower than the CN market (14% per year).
Hoge groei-inkomsten: 600420's revenue (7.6% per year) is forecast to grow slower than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: 600420's Return on Equity is forecast to be low in 3 years time (10.3%).